Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study incorporating bone marrow microenvironment (ME) - co-targeting bortezomib into tandem melphalan-based autotransplants with DTPACE [cisplatin + doxorubicin + cyclophosphamide + etoposide] for induction/consolidation and thalidomide + dexamethasone for maintenance

Next Previous
Trial Profile

A phase II study incorporating bone marrow microenvironment (ME) - co-targeting bortezomib into tandem melphalan-based autotransplants with DTPACE [cisplatin + doxorubicin + cyclophosphamide + etoposide] for induction/consolidation and thalidomide + dexamethasone for maintenance

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Melphalan; Thalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms TT-IIIB

    • Most Recent Events

    • 09 Apr 2024 Planned End Date changed from 1 Aug 2024 to 1 Aug 2025.
    • 09 Apr 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Aug 2025.
    • 06 Jun 2023 Results assessing three years maintenance with bortezomib, lenalidomide, and dexamethasone in multiple myeloma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top